Slide 1: Third Quarter 2020 Financial Results & Business Update
Third Quarter 2020 Financial Results & Business Update October 29, 2020 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the co
Slide 3: Agenda
Introduction Sandy Coombs, VP, Investor Relations Q3 2020 Financial Results; 2020 Financial Expectations Jim Frates, Chief Financial Officer Q3 2020 Commercial Review Todd Nichols, Chief Commercial Officer R&D Pipeline and Business Update Richard Pops, Chief Executive Officer Agenda
Slide 4: Third Quarter 2020 Financial Results Summary
Third Quarter 2020 Financial Results Summary In millions
Slide 5: Third Quarter 2020 Revenue Summary
Third Quarter 2020 Revenue Summary In millions, except % Q3’20 Q3’19 ∆ Q3’20 vs. Q3’19 VIVITROL® $80.3 $85.2 (6%) ARISTADA® $62.4 $53.6 16% Manufacturing & Royalty Revenue $120.4 $103.8 16% R&D and License Revenues $2.0 $12.7 (84%)* Total Revenue $265.0 $255.2 4% Amounts in the table above do not su
Slide 6: Financial Expectations for Year Ending Dec. 31, 2020
(in millions, except per share amounts) Financial Expectations for Year Ending Dec. 31, 2020 Revenues $1,010 – $1,035 COGS $180 – $190 R&D Expense $375 – $390 SG&A Expense $530 – $545 Amortization of Intangible Assets ~$40 Other Income, Net ~$30 Income Tax Expense $10 – $15 GAAP Net Loss ($95) – ($1
Slide 7: VIVITROL Performance
VIVITROL® Performance Q3 year-over-year net sales decline of 6% to $80.3M, driven by unit decline of 3% Sequential net sales increased 12% driven by unit growth of 22% Gross-to-net deductions: 53% in Q3’20, compared to 49% in Q3’19 and 46% in Q2’20 Inventory levels rebounded by ~6,500 units in Q3’20
Slide 8: ARISTADA Performance
ARISTADA® Performance Q3 year-over-year net sales growth of 16% to $62.4M, driven by unit growth of 20% Gross-to-net deductions: 54% in Q3’20, compared to 48% in Q3’19 and 53% in Q2’20 Increased gross-to-net adjustments in Q3’20 reflect increased Medicaid utilization Inventory levels increased ~1,90
Slide 9: ARISTADA: Prescription Growth Trends
ARISTADA®: Prescription Growth Trends Q3 year-over-year growth of 22% on TRx months of therapy (MOT) basis Outpaced overall atypical long-acting injectable (LAI) market Q3 year-over-year growth of 5% Market share: TRx MOT: 9% of atypical LAI market prescriptions in August 2020 Utilization of two-mon
Slide 10: ALKS 3831 Update
ALKS 3831 Update Payer engagement strategy Expect that access will improve throughout first year of launch as formulary decisions are made Plan to implement patient access programs designed to mitigate payer restrictions early in launch Sales force planning Focus on leveraging existing commercial or
Slide 11: ALKS 4230: Advancing the Clinical Development Program
ALKS 4230: Advancing the Clinical Development Program ARTISTRY-1 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress included evidence of ALKS 4230 antitumor activity, both as monotherapy and in combination with pembrolizumab, with durable and deepening responses obse
Slide 12: www.alkermes.com
www.alkermes.com